Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (August 2023)
26 slides from Netramark's investor presentation, August 2023
Slide 1: Corporate Presentation
CSE: AIAI CORPORATE PRESENTATION OTCQB: AINMF August 2023 FRA: 8TV
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and conta
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: Our Vision and Goals
The NetraMark vision is to have a material OUR VISION AND GOALS impact on the current 12% clinical trial success rate and serve the pharmaceutical industry’s demands for the efficient development of novel therapeutics and medicines. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 5: The Team: Leadership
We have assembled a highly experienced leadership team OFFICERS George Achilleos Josh Spiegel Dr. Joseph Geraci Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25+ 25-plus years of experience in finance,
Slide 6: The Team: Advisory Team
We have assembled a highly experienced advisory team STRATEGIC ADVISORS Dr. Larry Alphs Dr. MaryAnne Rizk Advisory Board Member Advisory Board Member Seasoned pharmaceutical industry veteran having served Dr. Rizk is a highly accomplished professional with a in leadership roles at major industry fir
Slide 7: The Pharmaceutical Industry
The AI pharmaceutical space THE PHARMACEUTICAL INDUSTRY Key problems to address: 1. There is a real challenge identifying molecules that address disease 2. There is a very low rate of success getting through the clinical trial process, in particular, Phase 2 and 3 3. There are real challenges identi
Slide 8: The Opportunity
We believe there is significant opportunity to improve the clinical trial process and reduce the associated cost BASIC DRUG PRE- FDA POST-APPROVAL CLINICAL TRIALS RESEARCH & RESEARCH DISCOVERY CLINICAL REVIEW MONITORING PHASE I PHASE II PHASE III PHASE IV THE OPPORTUNITY From drug discovery through
Slide 9: The Market
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Number of interventional clinical studies, past 12 months1 450,000 399,522 400,000 2,500 362,500 350,000 325,771 293,254 2,000 300,000 262,299 250,000 233,124 1,500 205,335 2,300 200,000 181,22
Slide 10: The Challenge
The challenge of using AI for clinical trials THE CHALLENGE The challenge centers around the ability to apply AI methods to small datasets and extract statistically significant insights that can be utilized to enrich future studies and reduce the associated costs CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 11: Over 95% of trials have less than 1,000 participants
Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. NE Cumulative # of trials by anticipated # of participants (1999 – 2021)* OG TTHHEE CSHOALLULTEIN 1-100
Slide 12: The NetraMark Approach
THE NETRAMARK APPROACH Clinical trial offering The pharmaceutical industry is looking for novel and proprietary ways to leverage data to help de-risk clinical trials by better directing efforts to enrich future clinical trial studies and reduce costs. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 13: The NetraMark Technologies
The core technologies NetraAI THE NETRAMARK TECHNOLOGIES Hypothesis Generation Platform for Clinical Data NetraPlacebo NetraGPT Optimize Study Response Instant Explainability of and Power Results NetraMark enables clients to optimize learnings from their data by providing an augmented intelligence e
Slide 14: Introducing NetraAI: Know Your Patients
Introducing NetraAI: Know Your Patients • NetraAI is built to uncover the hidden relationships between patients in a clinical trial by using novel methods and empowering scientists to make critical decisions NETRAMARK TECHNOLOGIES • It provides an unprecedented high-resolution perspective into how p
Slide 15: NetraMark Technologies: Pancreatic Cancer treatment study
Pancreatic Cancer treatment study Patient numbers in the dataset* Complete Response Partial Response Stable Disease Progressive Disease Totals Treatment Groups 1 70 98 49 218 FFX** 0 41 55 33 129 The NetraAI difference GnP*** 1 29 43 16 89 Perspective 1 - NetraMap NetraAI is a unique machine learnin
Slide 16: Introducing NetraPlacebo
Introducing NetraPlacebo • The top right-hand corner consists of an almost pure group of placebo non-responders to a bipolar Placebo Non- depression drug NETRAMARK TECHNOLOGIES Responders • The bottom left is a mixed group that was repelled away from the pure responder group and attracted together •
Slide 17: Introducing NetraGPT
Introducing NetraGPT • Output reports that begin to assemble in seconds and conclude within minutes • Improved explainability of the influential variables NETRAMARK TECHNOLOGIES underlying discovered subpopulations • Additional insights delineating interconnections among variables, the response, and
Slide 18: The Value
The Value De-risk and Increase the Efficiency of Clinical Trials Our machine learning methodologies are intended to accelerate traditional drug development through improved understanding of the underlying disease and mechanism of action with the expectation for improved clinical trial designs showca
Slide 19: The Go To Market Approach
The Target Engagement Biotech or pharma company programs with clinical data in an indication of experience in these areas: • Oncology • Neurology THE GO TO MARKET APPROACH • Psychiatry • Metabolic • Rare & Orphan Disorders The Target Audience Leverage high level relationships & attend disease specif
Slide 20: NetraAI Initial Customer Assessment
NetraAI Initial Customer Assessment • Entry level paid engagement model for Early Trial Phase • Consultive report deliverable that maximizes learnings from upcoming pre pivotal study to de-risk expensive later THE NETRAMARK APPROACH stage of clinical trial • NetraAI evaluates existing Phase I data,
Slide 21: NetraAI Pivotal Decision Support Solution
NetraAI Pivotal Decision Support Solution • Premium value engagement The role of NetraAI • Pre-pivotal – Phase II complete * THE NETRAMARK APPROACH • Comprehensive recommendations and analysis to support pivotal study plan • Create patient stratification datasets to inform enrichment criteria and em
Slide 22: NetraPlay Access and Support
NETRAPLAY NetraPlay Access and Support • Study specific subscription engagement • Populated with data from previous clinical studies and THE NETRAMARK APPROACH Netra Health Atlas • Ability for biotech/pharma discovery teams to further confirm MOA • Visualize and determine causal factors driving trea
Slide 23: The Business Model: Building the sales pipeline
Current Year YTD Results THE BUSINESS MODEL Building the sales pipeline 50+ Leads in the sales pipeline Leverage leadership pharmaceutical network 5+ CRO channel partner discussions Pharma Targeting outreach Aggressive conference schedule Build CRO channel strategy Sales pipeline lead list build to
Slide 24: The Market Comps
The Pharmaceutical AI sector is producing high valuation multiples Comparison Estimated Revenue Pre-Money Valuation Valuation / Rev Multiple Owkin1 2020 ~ $12.15M Nov 2021 ~ $1.12B ~ 92X ConcertAI1 2022 ~ $53M Mar 2022 ~ $1.75B ~ 33X THE MARKET COMPS GNS Healthcare2 ~ $14M Jan 2020 ~ $120M ~ 8.6X Pa
Slide 25: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 26: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is or
NetraMark Holdings — Investor Presentation (August 2023) on 6ix